Clinical Trials Browser

Phase 1/2 × NIH × Temozolomide × Clear all

NCT05432804 2026-05-18

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1/2 Recruiting

Glioblastoma

NCT05691491 2026-05-13

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Phase 1/2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04890093 2026-03-16

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1/2 Suspended

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase 1/2 Terminated

53 enrolled 22 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Phase 1/2 Completed

37 enrolled 19 charts

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT03190967 2023-10-11

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Phase 1/2 Terminated

12 enrolled 16 charts

Brain Neoplasms, Breast Neoplasms

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT00731731 2022-08-04

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1/2 Completed

125 enrolled 12 charts

Glioblastoma, Gliosarcoma

NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Phase 1/2 Completed

40 enrolled 32 charts

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01196416 2019-11-18

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Phase 1/2 Completed

14 enrolled 16 charts

Melanoma

NCT01514201 2019-08-13

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Phase 1/2 Completed

66 enrolled 24 charts

Astrocytoma, Glioblastoma, Gliosarcoma

NCT00305864 2018-03-05

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase 1/2 Completed

118 enrolled 10 charts

Glioblastoma, Gliosarcoma

NCT00085254 2016-02-25

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1/2 Completed

112 enrolled 14 charts

Glioblastoma, Gliosarcoma

NCT00014105 2013-12-04

Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 1/2 Unknown

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00811759 2010-10-07

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

Phase 1/2 Unknown

Melanoma